FRANKLIN LAKES, N.J., Nov. 6, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it is pledging up to $500,000, including $250,000 in cash and up to $250,000 in product donations, to support Hurricane Sandy relief efforts. BD’s cash commitment will be shared among the American Red Cross, the United Way, and several other nongovernmental humanitarian relief organizations with which BD regularly partners. In addition, BD will match donations made by BD employees to the American Red Cross, up to a total of $50,000.
BD’s product donations to AmeriCares, Heart to Heart International and Direct Relief International will support their hurricane response efforts, and the Company will continue to assess needs and seek additional opportunities to provide support. Products supplied to these organizations include syringes, insulin syringes, BD Sharps containers, alcohol swabs, lancets and BD Vacutainer® tubes.
“BD is committed to working with our trusted partners to support critical relief efforts following this historic storm that so severely impacted the east coast, including our home state of New Jersey,” said Vincent A. Forlenza, Chairman of the Board, Chief Executive Officer and President.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
Contacts:
Colleen T. White, Corporate Communications 201-847-5369;
colleen_white@bd.com
Monique N. Dolecki, Investor Relations 201-847-5378;
monique_dolecki@bd.com
SOURCE BD (Becton, Dickinson and Company)
